A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
暂无分享,去创建一个
F. de Marinis | V. Moreno | A. Hollebecque | N. Isambert | E. Angevin | S. Salvagni | K. Rihawi | A. Azaro | K. Dotti | M. Harnois | G. Spitaleri | S. Assadourian | A. Hervieu | Corinne Gomez | J. Rodón